Menu Search
Equities

Cellectis SA

ZVA:DUS

Cellectis SA

Actions
  • Price (EUR)1.73
  • Today's Change0.012 / 0.70%
  • Shares traded--
  • 1 Year change-31.62%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

  • Revenue in EUR (TTM)34.41m
  • Net income in EUR-99.60m
  • Incorporated2000
  • Employees235.00
  • Location
    Cellectis SA8, rue de la Croix JarryPARIS 75013FranceFRA
  • Phone+33 181691600
  • Fax+33 181691606
  • Websitehttps://www.cellectis.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.